GlassScriptPhysician profile
Alainna B Drieze
NPI 1720694334
$1,157.32
in general payments reported to CMS, 2019-2025
14 companies · $68.62 in 2025
The $68.62 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.84 · 2023: $565 · 2024: $458 · 2025: $68.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.02 | 2023-2025 | |
| Lilly USA, LLC | $150.85 | 2023-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $149.40 | 2022-2023 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $116.76 | 2023-2025 | Vaxelis, Gardasil 9, Vaqta |
| Exact Sciences Corporation | $65.51 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $65.39 | 2023-2024 | |
| Astellas Pharma US INC | $46.13 | 2023-2024 | Veozah |
| Novo Nordisk INC | $32.93 | 2024 | Ozempic, Rybelsus |
| Shield Therapeutics INC | $19.69 | 2023 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $19.21 | 2023 | Ajovy |
| Baxter Healthcare | $17.82 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lundbeck LLC | $16.69 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $16.45 | 2023 | Quviviq |
| Alkermes, INC. | $14.47 | 2023 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alainna Drieze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.